Close Menu

NEW YORK – NeuMoDx Molecular said on Friday that it received CE-IVD marking for its assay to detect and differentiate Trichomonas vaginalis and/or Mycoplasma genitalium in clinical urine samples.

The Ann Arbor, Michigan-based company has launched the assay, which is for use with NeuMoDx Molecular systems. The assay leverages nucleic acid amplification technology for the automated detection of T. vaginalis and M. genitalium simultaneously.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.